Deallus thought leadership

The latest from Deallus pharmaceutical and life science industry experts

How is COVID-19 impacting clinical trials?

2021-03-21T16:39:17+00:00Thought Piece|

As the impact of COVID-19 pandemic continues to expand globally, pharmaceutical and biotech players are beginning to feel the disruptive effects of the outbreak. New clinical trials will be significantly delayed as companies continue to face challenges arising from COVID-19, from potential patient quarantines, to site closures, travel limitations or interruptions to the supply chain for new investigational products.

Gene therapy through different lenses

2020-06-21T16:30:02+01:00Thought Piece|

After decades of clinical research and numerous setbacks, the promise of gene therapy is now much more than a glimmering hope on the horizon. Gene therapy is poised to revolutionize medicine as it presents the opportunity to remove or change the content of an individual’s genetic code in order to potentially treat or cure disease. We explore gene therapy from a few different lenses to give a full picture of where this innovation currently stands.

Head to head trials in elbow to elbow markets

2020-06-21T16:17:32+01:00Thought Piece|

Head to head trials are proving to be a powerful mechanism for the testing of competitive medicines. A tactic for those already on the market who are eager to expand their market share, it offers the promise of considerable commercial advantage. We explore what needs to be known about head to head trials, and how they might be put to use for products operating in a saturated, competitive market.

Go to Top